Ryan Specialty (RYAN)

NYSEFinancialsInsurance - BrokersSnapshot 2026-10-23

$43.68-1.82%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Ryan Specialty’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+0.7%

+10% or more+5%0%−5%−10% or less

2.41 → 2.43 EPS · FY ending Dec 31, 2027 · 11 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 11 to 11; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	794.33M
EPS	—	0.477
Annual ending 2026-12-31
Revenue	—	3.29B
EPS	—	2.164
Annual ending 2027-12-31
Revenue	—	3.53B
EPS	—	2.431

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Share repurchase program expanded to $600 million	The company repurchased $260 million in shares recently, expanding its buyback program to $600 million.	Intact	Share repurchase program reduced below $600 million or buybacks halt	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. The share repurchase program was initially authorized at $300 million in 2025-Q4 and 2026-Q1, then increased by $300 million to $600 million total authorization by 2026-Q2. The company repurchased $260 million of shares in 2026-Q2, demonstrating active capital return. The trajectory is delivering on the expanded repurchase authorization. Delivery assessment Oct 24, 2026
Maintain quarterly dividend of $0.13 per share	A supporting condition in Ryan Specialty's published investment case. The stated target is Quarterly dividend of $0.13 per share.	Intact	Dividend cut below $0.13 per share	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. The company maintained a quarterly dividend of $0.13 per share in 2026-Q1 and 2026-Q2, up from $0.12 in 2025-Q3. Dividend payments have been consistent and the company declared the dividend regularly, indicating delivery on this capital allocation priority. Delivery assessment Oct 24, 2026
Adjusted EBITDAC margin decline limited to 100-150 basis points in 2026	A primary condition in Ryan Specialty's published investment case. The stated target is Adjusted EBITDAC margin down 100-150 bps in FY26.	Intact	Margin decline exceeds 150 basis points in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. The company updated 2026 guidance to Adjusted EBITDAC Margin down 50-100 basis points from prior guidance of 100-150 basis points decline. Actual margin was 35.7% in 2026-Q2, slightly down from 36.1% in 2025-Q2, showing limited margin contraction. The trajectory is mixed with modest margin decline consistent with guidance. Delivery assessment Oct 24, 2026
Revenue growth of about 7.6% to 8% per year	Ryan Specialty grows revenue about 8% a year.	Improving	YoY revenue growth falls below 7.6% next year	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$2.43

$2.35 → $2.43 · observed estimates

FY2027 revenue$3.53B

$3.51B → $3.53B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$2.35	$3,505,724,340	19 / 15
2026-07-25	$2.35	$3,505,724,340	19 / 15
2026-07-26	$2.35	$3,505,724,340	19 / 15
2026-07-27	$2.34	$3,506,732,065	10 / 11
2026-07-28	$2.34	$3,506,732,065	10 / 11
2026-07-29	$2.35	$3,505,724,340	19 / 15
2026-07-30	$2.34	$3,506,732,065	10 / 11
2026-07-31	$2.34	$3,509,609,252	10 / 11
2026-08-01	$2.34	$3,509,609,252	10 / 11
2026-08-02	$2.40	$3,521,349,810	18 / 15
2026-08-03	$2.38	$3,526,491,899	10 / 10
2026-08-04	$2.40	$3,521,349,810	18 / 15
2026-08-05	$2.41	$3,525,152,630	19 / 16
2026-08-06	$2.38	$3,526,491,899	10 / 10
2026-08-08	$2.41	$3,526,740,130	19 / 16
2026-08-09	$2.38	$3,526,491,899	10 / 10
2026-08-10	$2.41	$3,526,740,130	19 / 16
2026-08-12	$2.41	$3,532,789,470	19 / 15
2026-08-13	$2.38	$3,526,491,899	10 / 10
2026-08-14	$2.38	$3,526,491,899	10 / 10
2026-08-15	$2.38	$3,526,491,899	10 / 10
2026-08-16	$2.38	$3,526,491,899	10 / 10
2026-08-17	$2.38	$3,526,491,899	10 / 10
2026-08-18	$2.38	$3,526,491,899	10 / 11
2026-08-19	$2.38	$3,526,491,899	10 / 11
2026-08-20	$2.42	$3,534,140,939	11 / 12
2026-08-21	$2.42	$3,534,140,939	11 / 12
2026-08-22	$2.42	$3,534,140,939	11 / 12
2026-08-23	$2.42	$3,534,140,939	11 / 12
2026-08-24	$2.42	$3,534,140,939	11 / 12
2026-08-25	$2.42	$3,534,140,939	11 / 12
2026-08-26	$2.41	$3,534,140,939	11 / 12
2026-08-27	$2.41	$3,534,140,939	11 / 12
2026-08-28	$2.41	$3,534,140,939	11 / 12
2026-08-29	$2.41	$3,534,140,939	11 / 11
2026-08-30	$2.41	$3,534,140,939	11 / 11
2026-08-31	$2.41	$3,534,140,939	11 / 11
2026-09-01	$2.41	$3,534,140,939	11 / 11
2026-09-02	$2.41	$3,534,140,939	11 / 11
2026-09-03	$2.41	$3,534,140,939	11 / 11
2026-09-04	$2.41	$3,534,140,939	11 / 11
2026-09-05	$2.41	$3,534,140,939	11 / 11
2026-09-06	$2.41	$3,534,140,939	11 / 11
2026-09-07	$2.41	$3,534,140,939	11 / 11
2026-09-08	$2.41	$3,534,140,939	11 / 11
2026-09-09	$2.41	$3,534,140,939	11 / 11
2026-09-10	$2.41	$3,534,140,939	11 / 11
2026-09-11	$2.41	$3,534,140,939	11 / 11
2026-09-12	$2.41	$3,534,140,939	11 / 11
2026-09-13	$2.41	$3,534,140,939	11 / 11
2026-09-14	$2.41	$3,534,140,939	11 / 11
2026-09-15	$2.41	$3,534,140,939	11 / 11
2026-09-16	$2.41	$3,534,140,939	11 / 11
2026-09-17	$2.41	$3,534,140,939	11 / 11
2026-09-18	$2.41	$3,534,140,939	11 / 11
2026-09-19	$2.41	$3,534,140,939	11 / 11
2026-09-20	$2.41	$3,534,140,939	11 / 11
2026-09-21	$2.41	$3,534,140,939	11 / 11
2026-09-22	$2.41	$3,534,140,939	11 / 11
2026-09-23	$2.41	$3,534,140,939	11 / 11
2026-09-24	$2.41	$3,534,140,939	11 / 11
2026-09-25	$2.41	$3,534,140,939	11 / 11
2026-09-26	$2.41	$3,534,140,939	11 / 11
2026-09-27	$2.41	$3,534,140,939	11 / 11
2026-09-28	$2.41	$3,534,140,939	11 / 11
2026-09-29	$2.41	$3,534,140,939	11 / 11
2026-09-30	$2.41	$3,534,140,939	11 / 11
2026-10-01	$2.41	$3,534,849,751	11 / 11
2026-10-02	$2.41	$3,534,089,023	11 / 12
2026-10-03	$2.41	$3,534,089,023	11 / 12
2026-10-04	$2.41	$3,534,089,023	11 / 12
2026-10-05	$2.41	$3,534,089,023	11 / 12
2026-10-06	$2.41	$3,534,089,023	11 / 12
2026-10-07	$2.43	$3,534,089,023	11 / 12
2026-10-08	$2.43	$3,528,151,523	11 / 12
2026-10-09	$2.43	$3,528,151,523	11 / 12
2026-10-10	$2.43	$3,528,151,523	11 / 12
2026-10-11	$2.43	$3,528,151,523	11 / 12
2026-10-12	$2.43	$3,528,151,523	11 / 12
2026-10-13	$2.43	$3,527,976,085	11 / 12
2026-10-14	$2.43	$3,529,941,760	11 / 12
2026-10-15	$2.43	$3,529,941,760	11 / 12
2026-10-16	$2.43	$3,529,941,760	11 / 12
2026-10-17	$2.43	$3,529,941,760	11 / 12
2026-10-18	$2.43	$3,529,941,760	11 / 12
2026-10-19	$2.43	$3,529,941,760	11 / 12
2026-10-20	$2.43	$3,529,941,760	11 / 12
2026-10-21	$2.43	$3,529,941,760	11 / 12
2026-10-22	$2.43	$3,529,941,760	11 / 12
2026-10-23	$2.43	$3,529,941,760	11 / 12
2026-10-24	$2.43	$3,529,941,760	11 / 12

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	12	7	1
2026-06-01	11	8	1
2026-07-01	10	9	1
2026-08-01	9	9	1
2026-09-01	9	9	1
2026-10-01	9	9	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 9 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades3 maintains

Recent actions · Sep 25–Oct 24 · 3 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Mizuho SecuritiesOct 7 · prior Sep 16

$43.00 → $40.00-7.0%

Piper SandlerOct 6 · prior Jul 31

$48.00 → $40.00-16.7%

$0$26.40$52.80

0 raises · 2 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Share repurchase program expanded to $600 millionDirect metric needs a verified mapping
Maintain quarterly dividend of $0.13 per shareDirect metric needs a verified mapping
Adjusted EBITDAC margin decline limited to 100-150 basis points in 2026Direct metric needs a verified mapping
Revenue growth of about 7.6% to 8% per yearDirect metric needs a verified mapping

Next proof point

Oct 29, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.6%Typical daily move · historical

Downside history

-49.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Ryan Specialty outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

RYAN is a financials growth and capital-return business, with recent results supporting its long-term thesis. Its thesis state is intact, but execution quality is described as weak and management as volatile, so the evidence does not support treating the business as a low-risk compounder.

What's priced into Ryan Specialty

The valuation evidence describes RYAN as expensive, and the expectations gap is elevated, meaning expectations appear demanding relative to the evidence available. Confidence in the valuation model is low, so the precise degree of optimism already reflected in the valuation is uncertain.

What the fundamentals likely do

Near-term results have been strong: organic revenue growth was 11.8% in 2026-Q1 and 6.7% in 2026-Q2, against management’s mid-single-digit goal for 2026. Repurchases and the quarterly dividend are on track, while the recent earnings beat supports the business setup. Near-term risk remains elevated because of fragile earnings quality, a history of a deep miss, and recent peer misses; a guidance cut on the next call would be a meaningful negative.

What Ryan Specialty hinges on

The multi-year view hinges on RYAN sustaining organic growth while maintaining execution quality. A guidance cut or Fed rate cuts would weigh on the near-term setup; continued earnings strength and higher guidance from sector peers MRSH, AJG, and AON would support sector momentum. These scenarios are uncertain, and overall confidence is medium.